Sugi Predict

Sugi Predict / Targets / XPO1

XPO1

Exportin-1 · O14980 · XPO1 on Sugi Atlas →

9,664 patent compounds predicted against XPO1, 5,089 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1333897 SCHEMBL1333897 1.00 20/20
SCHEMBL1333900 SCHEMBL1333900 1.00 20/20
SCHEMBL1333903 SCHEMBL1333903 1.00 20/20
SCHEMBL1336103 SCHEMBL1336103 0.89 20/20
SCHEMBL1336104 SCHEMBL1336104 0.89 20/20
SCHEMBL1336105 SCHEMBL1336105 0.89 20/20
SCHEMBL1336042 SCHEMBL1336042 0.85 20/20
SCHEMBL1336048 SCHEMBL1336048 0.85 20/20
SCHEMBL1335090 SCHEMBL1335090 0.80 20/20
SCHEMBL1336418 SCHEMBL1336418 0.80 20/20
SCHEMBL1336420 SCHEMBL1336420 0.80 20/20
SCHEMBL1335130 SCHEMBL1335130 0.78 20/20
SCHEMBL1335132 SCHEMBL1335132 0.78 20/20
SCHEMBL1335134 SCHEMBL1335134 0.78 20/20
SCHEMBL1335249 SCHEMBL1335249 0.78 20/20
SCHEMBL1335250 SCHEMBL1335250 0.78 20/20
SCHEMBL1335251 SCHEMBL1335251 0.78 20/20
SCHEMBL1333949 SCHEMBL1333949 0.73 20/20
SCHEMBL1333953 SCHEMBL1333953 0.73 20/20
SCHEMBL1335010 SCHEMBL1335010 0.73 20/20

Clinical trials — most relevant to XPO1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] PHASE3COMPLETED
Efficacy and Safety Study of XP12B in Women With Menorrhagia PHASE3COMPLETED
Safety Study of XP12B in Women With Menorrhagia PHASE3COMPLETED
Efficacy and Safety of XP12B in Women With Menorrhagia PHASE3COMPLETED
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma PHASE2RECRUITING
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study PHASE2RECRUITING
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis PHASE2ACTIVE_NOT_RECRUITING
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors PHASE2RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) PHASE2RECRUITING
Selinexor, Cyclophosphamide and Prednisone in Myeloma PHASE2COMPLETED
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT PHASE2NOT_YET_RECRUITING
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients PHASE1/PHASE2UNKNOWN
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma PHASE2COMPLETED
Avapritinib Maintenance for AML With KIT Mutations PHASE2NOT_YET_RECRUITING
XPO-1 in Combination With RCHOP for DH/TH Lymphoma PHASE2UNKNOWN
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) PHASE2RECRUITING
A Trial of Selinexor, Ruxolitinib and Methylprednisolone PHASE1RECRUITING
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients PHASE1COMPLETED
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE1COMPLETED
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma PHASE1UNKNOWN
Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer PHASE1UNKNOWN
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies PHASE1COMPLETED
Treatment of Chronic Lymphocytic Leukemia nanUNKNOWN
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes nanCOMPLETED
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma nanACTIVE_NOT_RECRUITING
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum nanCOMPLETED
Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a XPO1 binder may also engage these)

ProteinNameSimilarity
Q80U96 — 1.000 Q80U96 →
Q6P5F9 — 1.000 Q6P5F9 →
P17427 — 0.970 P17427 →
P18484 — 0.969 P18484 →
P52296 — 0.966 P52296 →
P52297 — 0.965 P52297 →
AP2A2 AP-2 complex subunit alpha-2 0.965 landscape →
P70168 — 0.960 P70168 →
KPNB1 Importin subunit beta-1 0.960 landscape →
Q0VCK5 — 0.956 Q0VCK5 →
Q8BFY9 — 0.954 Q8BFY9 →
PSMD1 26S proteasome non-ATPase regulatory subunit 1 0.953 landscape →
TNPO1 Transportin-1 0.951 landscape →
Q3SYU7 — 0.950 Q3SYU7 →
O14787 — 0.949 O14787 →
Q5R5S4 — 0.949 Q5R5S4 →
Q3TXS7 — 0.947 Q3TXS7 →
DHX9 ATP-dependent RNA helicase A 0.945 landscape →
O88761 — 0.945 O88761 →
Q5F418 — 0.944 Q5F418 →
Q99LD4 — 0.943 Q99LD4 →
Q5R874 — 0.943 Q5R874 →
P61203 — 0.943 P61203 →
Q6GR10 — 0.941 Q6GR10 →
P97834 — 0.941 P97834 →
Q7SXR3 — 0.941 Q7SXR3 →
COPS2 COP9 signalosome complex subunit 2 0.940 landscape →
CUL4A Cullin-4A 0.940 landscape →
Q6IQT4 — 0.940 Q6IQT4 →
P61202 — 0.939 P61202 →